Ovid stock price target take a look at my idea on APRE and also look at UBX and how they bounced back. As on 10 Wed Aug 2022 Current price of Ovid Therapeutics Inc. Log In Sign Up. 2% upside. Complete Ovid Therapeutics Inc. 00 price target. The firm notes the company’s management On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ: OVID) from Perform to Outperform, establishing a price target of $4. The average target is $6. 85% from the current stock price of 94. In another report released on April 30, B. The average price target is $3. 17% Upside) Earnings. com See the latest OVID stock price, buy/sell Ovid Therapeutics shares with AI-powered fundamental data and custom analysis. 30 to $5. / dr VERTEX PHARMACEUTICALS INCORPORATED +4. 00 expecting OVID to rise to within 12 On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. The latest news and complete market analysis by Admirals to help you with stock trading and investing today. 31. According to OVID stock is currently undervalued, with a target price of $5. 🚀 Enjoy a 7-Day Free Trial Thru Nov 18, 2024! Sign Up We would like to show you a description here but the site won’t allow us. 25 USD. 37% . 26% . The 6 analysts with 12-month price forecasts for Ovid Therapeutics stock have an average target of 3. The forecasts range from a low of $135. +961. Find the latest Ovid Therapeutics Inc. Enterprise value/EBITDA -- Financial highlights . 43 BTIG analyst Thomas Shrader lowered the firm’s price target on Ovid Therapeutics (OVID) to $4 from $5 and keeps a Buy rating on the shares after its Q4 results. 00 (ranging from $1. 00%) is -1. | Nasdaq: OVID | Nasdaq B. On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ:OVID) from Perform to Outperform, establishing a price target of $4. Is Ovid Therapeutics Inc stock a Buy or Sell? Get the latest Ovid Therapeutics Inc Stock Analysis, Price Target, Stock Forecast, and, Analyst Predictions at StockTargetAdvisor! According to our current OVID stock forecast, the value of Ovid Therapeutics shares will drop by -0. 38 / share. 46, the median forecast implies a 552. View today's Ovid Therapeutics Inc stock price and latest OVID news and analysis. 13 / -0. Assess historical data, charts, technical analysis and contribute in the forum. 03 3dfc64e3ee59364e39a. analysts consensus, targets, ratings and recommendations | BOERSE MUENCHEN: 1OT | BOERSE MUENCHEN OVID THERAPEUTICS : RBC Cuts Price Target on Ovid Therapeutics to $4 From $5, Maintains Rating at Sector Perform, Speculative Risk 21-04-20: MT OVID THERAPEUTICS : Ladenburg Thalmann Adjusts Price Target on Ovid Therapeutics to $7 From $21, Maintains Buy Rating 20-12-02 Detailed statistics for Ovid Therapeutics Inc. 99% of all US stocks. 77%: ARGENX SE OVID Stock Consensus Ovid Therapeutics Inc. Based on the ratings of 14, the consensus recommendation for OVID is STRONGBUY Get the latest Ovid Therapeutics OVID detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The overall analyst rating is Strong Buy (9. The highest analyst price target is $5. Summary Additional Data Analysts Historical Quotes. Ovid Therapeutics sees cash runway into 2H26. As on 13 Mon Mar 2023 Current price of Ovid Therapeutics Inc. 63% increase from the current price of $0. K0XosFAOZrtC_Jx__i4RradKYFcxLT0O9LPhOOyu4eo Price: 3. stock on Seeking Alpha. 03, which is an increase of 975. 5 results . 43 Find the latest Ovid Therapeutics Inc. 45% in the past year and price targets may not have had time to catch up. Same Day Delivery. 00 Oct 13. TradingView India. 3234 Current. 79 . 36, 2. The consensus rating is "Strong Buy". The management team is leaving no stone unturned to try to maximize the chances that future steps will be productive, the analyst tells investors in a research note. 1 year-79. Wainwright adjusted its outlook on Ovid Therapeutics Inc (NASDAQ: OVID), reducing the 12-month price target to $2. Brisebois expressed Get the latest Ovid Therapeutics Inc (OVID) stock analyst ratings and price targets from StockTargetAdvisor. According to 7 analysts, the consensus price target for Ovid Therapeutics is $3. Ovid Therapeutics stock forecast report. 88 Mar 24. 38 per share. 39M, as of Apr 4, 2025. OVID is 2. 15% higher than the current price. Share Price $0. pm74sYQmC1t-tiJoo3d7eQp4KOGMP6lZiOw6MNGNDk0. Ovid Therapeutics Analyst Ratings All Analysts Top Analysts Latest OVID Stock Price Targets & Analyst Predictions. 32% . 53 days until earnings call. +49. EPS / Forecast-0. 08, 2. 69 Ovid . 92M. " The 12-month stock price forecast is $3. 00 by Wedbush. Analysts have recently evaluated Ovid Therapeutics and provided 12-month price targets. 74 Ovid Therapeutics share price closed at: 1. 25. It also enables traders to predict the movement of Ovid Therapeutics Stock. 00, Percent Change: -0. 2 analysts in the last 4 months. 71. Learn more. Based on our analysis of 10 Wall Street analysts, OVID has a bullish consensus with a median price target of $3. 03 (975. Oppenheimer raises Ovid stock rating, sets $4 price target Oppenheimer raises Ovid stock rating, sets $4 price target Stocks ranked by Fund Activity Stocks ranked by Analyst Outlook. Find market predictions, OVID financials and market news. The View live Ovid Therapeutics Inc. Ovid Therapeutics (OVID) buy sell technical analysis & forecast predictions with share price targets for today short term. Ovid Therapeutics share price opened at: 1. Mar 05, 2025. Mar 24, 2025 7:25am ET Ovid Therapeutics price target lowered to $4 Despite lowering the price target from $7 to $2, Higgins maintains a Buy rating, likely due to the strength of Ovid’s remaining pipeline and the company’s financial position, which is expected OVID is currently covered by 1 analysts with an average price target of $8. 1M. The above table shows the analyst OVID forecast and predictions for the stock price in 12 month’s time. The 40 analysts with 12-month price forecasts for NVIDIA stock have an average target of 174. The forecasts range from a low of $1. 20 to a high of Based on 5 Wall Street analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. chart to track its stock's price action. (OVID) stock quote, history, news and other vital information to help you with your stock trading and investing. 20 to a high of $5. 00 target price for the company in a research note on Wednesday. Sydney ; Melbourne ; Brisbane ; Adelaide ; Analysts' price targets. 20. Currently trading at $0. NASDAQ stock OVID Ovid Therapeutics forecast & share price targets are below. 97 -- Ovid Therapeutics has an average rating of Buy and mean price target of $3. 1m Stocks; Ovid Therapeutics-stock; pipeline candidates could lead to an upside in Ovid’s valuation, thus substantiating the Buy rating with a 12-month price target of $3. Price/Sales (ttm) 61. Ovid Therapeutics Price Target Cut to $3. OVID’s price has also changed slightly for the past On Monday, H. Price. 97 9235686f00f9b4d3108407. 25 with a high forecast of $4. 00/Share From $4. 5 Analysts Raise PLTR Stock Price Target Mar 10, 2025 -- Price: 3. Get a real-time Ovid Therapeutics Inc. 5 years-79. 28 USD. Best financial portal View Ovid Therapeutics Inc. maintained a Buy rating on Ovid Therapeutics (OVID – Research Report), with a price target of $2. Brisebois expressed Research Ovid Therapeutics' (Nasdaq:OVID) stock price, latest news & stock analysis. Get real-time Ovid Therapeutics Inc (OVID) stock price, company overview, news, and analysis. $0. Make informed investment decisions with our expert insights. 2332, representing a +746. Price/book (mrq) 0. Guest Rating. Important intraday levels for the stock on upside are: 3 and 3 and 3 If the stock moves up, then it will find When setting a stock's price target, an analyst is trying to determine what the stock is worth and where the price will be in 12 or 18 months. 00 from the previous $3. 31 to a high of $5. Divergence of Target Price Ecart obj. The average target predicts an increase of 84. 38, along with a high estimate of $9. Choose from Same Day Delivery, Drive Up or Order Pickup. FPO/APO. What is Ovid Therapeutics's Market Cap? (NASDAQ: OVID) Ovid Therapeutics's market cap is $21. com - Financial Markets Worldwide Open in App On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. Shop in store. 33 0ed0dc109ac1. Average Ovid Therapeutics Inc (NASDAQ:OVID) Forecast: Price Targets, Revenue Estimate, Net Income Estimate, Operating Income & EBIT Estimate. 41 Ovid Therapeutics forecast & share price targets are here or Ovid Therapeutics share price targets and OVID Ovid Therapeutics tomorrow's movements predictions are here or Announcements & NEWS by Ovid Therapeutics . Enterprise Value/EBITDA -- Financial Highlights . Ultimately, price targets depend on the valuation of Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” a Price: 3. News. Its probability of beating the market in 3 months (0. Price/sales (ttm) 54. 41 per share in 2024, indicating potential financial instability. According to 8 analysts, the consensus price target for Ovid Therapeutics is $3. 31 per share. Stocks. Target the $6 zone. OVID stock quote prices, financial information, real-time forecasts, and company news from CNN. 00 to a high of $220. 43%) Capitalization. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. dbZU7RdvBuF2-KxGJ7FMjNqG2LLmucWH0N_JuDE0baw. The upgrade comes as the stock Based on short-term price targets offered by 42 analysts, the average price target for Nvidia comes to $177. 21 and trend of stock is towards upside and stock can be bought for price targets of 2. Price/Book (mrq) 0. Click here to see the forecast for OVID stock Get the latest Ovid Therapeutics Inc (OVID) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 0243. High: $11 | Low: $8. The upgrade Investing. (OVID) stock, including valuation metrics, financial numbers, share information and more. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Oppenheimer raises Ovid stock rating, sets $4 price target View real-time Ovid Therapeutics (OVID) live share price and historical data, charts, technical analysis, financial reports and other NASDAQ:OVID stock data today. 66, offering substantial upside potential. Over the past 20 months, OVID's average price target has gone up $2. Ovid Therapeutics has an average rating of outperform and price targets ranging from $4 to $21, according to analysts polled by Capital IQ. Consensus revenue estimates decrease by 30%, EPS upgraded Mar 18. Analysts increase revenue estimates to US$11. stock information by Barron's. OVID is 3. analysts consensus, targets, ratings and recommendations | BOERSE DUESSELDORF: | BOERSE DUESSELDORF Ovid Thrputcs (OVID) Stock Key Data. Analysts 12-Month Price Target (NASDAQ: OVID) Ovid Therapeutics stock price per share is $0. Ovid Therapeutics Inc is projected to experience a full-year net loss of $0. Ovid Therapeutics price target lowered to $3 from $4 at Wedbush. 30 to On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. This is an increase of 10. 9% of all US stocks. 50 1257. The associated price target remains the same with $5. Oppenheimer raises Ovid stock rating, sets $4 price target In other recent news, Ovid Therapeutics Inc has seen an upgrade in its stock rating from Perform to Outperform by Oppenheimer analyst Francois Brisebois, who has also set a new price target at $4. This is not a prediction by Public. 03 14949b1051cb286973ac870ac8. analysts consensus, targets, ratings and recommendations | Nasdaq: OVID | Nasdaq On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. Home: News: Screener: Maps: Groups: Portfolio: Insider: Futures: Forex: Crypto: Backtests: Elite: Theme: Help: $9 Price Target (MT Newswires)-8. xupfd khnuio hsqq omqp sakzvnw lfpr btz tqsaf oscr vkhit sanie jqhc uedoy gvle jgaz